International Journal of Pharmaceuticals and Health care Research (IJPHR)

IJPHR |Vol.13 | Issue 2 | Apr - Jun -2025

www.ijphr.com

DOI : https://doi.org/10.61096/ijphr.v13.iss2.2025.237-243

ISSN: 2306-6091

Review

Targeting G-Protein-Coupled Receptors in Modern Drug Discovery: Advances and Therapeutic Potential

Kancharla Serafina[1], Kankanala Navya[1], Vemavarapu Satish Kumar[2]

[1]Intern, Clinoxy Solutions Pvt., Ltd., KPHB 9th Phase, Kukatpally, Back Side Nexus Mall (Forum Mall), Near JNTUH University. Hyderabad. Telangana. 500085
[2]Founder, Clinoxy Solutions Pvt., Ltd., KPHB 9th Phase, Kukatpally, Back Side Nexus Mall (Forum Mall), Near JNTUH University. Hyderabad. Telangana. 500085

*Author for Correspondence: Kancharla Serafina
Email: serafinakancharla@gmail.com

Published on: 20 May 2025

Published by:
DrSriram Publications

Abstract

G-Protein Coupled Receptors (GPCRs) are the largest and most varied group of membrane proteins. They are essential for converting signals from outside the cell into actions inside the cell. GPCRs play important roles in many body functions, including how we transmit signals in the brain, regulate the immune system, and manage hormones. They are involved in various diseases as well, such as cancer, heart problems, and brain disorders. This review looks at the latest advancements in finding drugs that target GPCRs. It highlights recent successes in designing drugs based on GPCR structures, the development of drugs that change GPCR activity in different ways, and the use of machine learning to predict how substances will interact with these receptors. It also discusses new approaches using RNA therapies and synthetic biology to influence GPCRs. Furthermore, the review focuses on innovative strategies for targeting less understood GPCRs and hidden allosteric sites, which have significant potential for new treatments. The combination of computer tools, omics technologies, and structural biology is creating new opportunities in precise drug development, making GPCRs a promising area for new medicines.

Keywords: G-Protein Coupled Receptors, Drug Discovery, Structure-Based Drug Design, Allosteric Modulation, Machine Learning, RNA Therapeutics, Synthetic Biology, Orphan GPCRs, Cryptic Sites, Drug Development.

INTRODUCTION

G-protein coupled receptors (GPCRs) constitute an essential class of receptors responsible for mediating a wide range of physiological responses to external stimuli. They are involved in everything from sensory perception (vision, taste, smell) to complex processes such as immune response regulation, neurotransmission and hormonal control. These receptors, including over 800 types in humans, are integral to normal physiological

functions and the pathophysiology of various diseases [1]. The significant pharmacological importance of GPCRs is evident in that around 34% of FDA-approved medications target these receptors. Their capability to undergo conformational changes upon ligand binding renders GPCRs extremely versatile, allowing them to activate G-proteins and influence several intracellular signalling pathways. [2][15]. These signalling pathways can regulate gene expression, ion channel function, and cellular metabolism, among various other processes. Due to their crucial involvement in health and disease, GPCRs offer a valuable opportunity for therapeutic intervention.

However, despite their vast therapeutic potential, GPCRs are challenging drug targets due to their dynamic structures, the complexity of their signalling mechanisms, and the occurrence of off-target effects. Traditional drug discovery approaches have primarily focused on targeting Ortho steric sites the main ligand-binding domains. However, recent innovations have expanded the scope of drug discovery to include allosteric sites, orphan receptors, and cryptic binding pockets, all of which offer new avenues for therapeutic intervention [3].

Structural Insights and Structure-Based Drug Design

The breakthrough in GPCR structural biology has significantly accelerated the development of selective and efficacious drugs targeting these receptors. Recent advances in high-resolution techniques, such as X-ray crystallography and cryo-electron microscopy (cryo-EM), have enabled researchers to visualize GPCRs in unprecedented detail [2][3][14]. The first structures of GPCRs, such as the β2-adrenergic receptor, provided critical insights into receptor-ligand interactions and helped establish frameworks for structure-based drug design. These structures, often bound to antagonists or agonists, reveal detailed information about the receptor's transmembrane helices, extracellular loops, and intracellular domains.

Structure-based drug design enables the logical creation of new ligands by offering a detailed outline of receptor structure and how it interacts with ligands. By employing computational docking, virtual screening, and molecular dynamics simulations, scientists can estimate the binding affinity and specificity of potential drug candidates. Additionally, recent progress in cryo-EM has made it possible to visualize the conformational changes that take place during ligand binding and receptor activation, providing valuable insights into the dynamic aspects of GPCR signalling.[3].

For instance, the discovery of biased ligands compounds that selectively activate certain signalling pathways while leaving others unaffected has opened new possibilities for developing drugs with fewer side effects. These biased agonists can exploit specific signalling pathways relevant to a particular disease state while avoiding undesired effects associated with other pathways [4]. Such discoveries are revolutionizing how GPCRs are targeted in drug development.

Allosteric Modulation

Unlike conventional Ortho steric ligands that attach to the main active site of a receptor, allosteric modulators connect to different sites on the receptor, impacting its activity more subtly. Allosteric modulation presents various benefits compared to Ortho steric modulation, such as enhanced specificity, decreased desensitization, and the ability to delicately adjust receptor function.[6].



Fig:1: Class A GPCR Allosteric Modulators

Allosteric modulators can be divided into two categories: positive allosteric modulators (PAMs), which boost receptor function and negative allosteric modulators (NAMs), which reduce receptor activity. One notable benefit of allosteric modulation is its capability to selectively target specific receptor subtypes while avoiding others, thereby reducing off target effects. Recent research has discovered various small molecule allosteric modulators for GPCRs, many of which hold potential for the treatment of neurological disorders, cardiovascular illnesses, and cancer. [5].

Allosteric modulators provide unique opportunities for the targeted manipulation of G protein-coupled receptors (GPCRs) that are characterized by intricate and multifaceted signalling mechanisms or that exhibit various active conformational states. By engaging with the receptor in an allosteric manner, these drugs can precisely influence the structural conformation of the receptor itself, leading to a controlled modulation of it's signalling output. This approach is particularly advantageous in scenarios where conventional Ortho steric agonists—molecules that bind to the primary active site—or antagonists fall short, such as in the intricate modulation of receptors that play pivotal roles in conditions involving pain, anxiety, and schizophrenia. This allows for a more nuanced therapeutic strategy that can enhance efficacy and reduce side effects compared to traditional methods.

Machine Learning and Computational Approaches

The integration of machine learning (ML) and artificial intelligence (AI) in the field of drug discovery has experienced remarkable growth in recent years, particularly in the development of therapies targeting G protein coupled receptors (GPCRs). GPCRs are critical components in numerous physiological processes and are pivotal targets for a wide array of pharmaceuticals. Machine learning algorithms have emerged as powerful tools in this domain, as they can adeptly predict interactions between GPCRs and various ligands, thus significantly expediting the process of new drug discovery.

To achieve this, researchers leverage vast datasets encompassing protein sequences, detailed molecular interactions, and comprehensive biological activity profiles. These datasets provide the foundational input for AI driven models. By employing sophisticated computational techniques, these models can analyse patterns and draw insights that humans may overlook. For instance, machine learning can unveil the structural features of ligands that are most likely to bind effectively with specific GPCR subtypes.

Furthermore, this predictive capability allows researchers to allocate their resources more efficiently by prioritizing the most promising drug candidates for further development and testing. This not only streamlines the drug discovery process but also increases the likelihood of identifying successful therapies that may translate into clinical applications more swiftly. As a result, the collaboration between machine learning and drug discovery represents a transformative paradigm in addressing therapeutic needs and advancing personalized medicine.[7].

An exciting approach in the field of machine learning involves the utilization of protein language models, such as GPCR-BERT. This innovative model is specifically trained on vast datasets comprising receptor sequence information. Its primary function is to accurately predict interactions between ligands and receptors, demonstrating impressive precision in its forecasts. This capability has the potential to significantly enhance our understanding of biological processes and aid in drug discovery efforts.[8]. Such computational tools are invaluable for the high-throughput screening of compound libraries and for de novo ligand design, allowing researchers to identify promising molecules without the need for extensive experimental testing.

Additionally, the field of computational chemo genomics has made significant strides by integrating chemical structure data with genomic and pharmacological information. This interdisciplinary approach has facilitated the identification of novel ligands for G protein-coupled receptors (GPCRs) across various receptor subfamilies. By leveraging advanced computational techniques and algorithms, researchers can analyse vast datasets to uncover potential new interactions and enhance our understanding of GPCR biology. This has important implications for drug discovery, as it opens up new avenues for the development of targeted therapeutics that can selectively engage specific GPCR subtypes, ultimately improving treatment outcomes for various diseases.[9]. By leveraging data sourced from public databases combined with sophisticated high-throughput assays, artificial intelligence models possess a remarkable ability to predict the pharmacological properties of new chemical entities. This predictive power is instrumental in the drug discovery process, as it aids researchers in identifying compounds that not only demonstrate high selectivity for their intended targets but also exhibit enhanced efficacy in therapeutic applications.

The integration of these advanced AI models streamlines various stages of drug development by reducing the time and resources typically required for initial screening and optimization of potential therapeutics. This efficiency accelerates the identification of promising candidates, thereby increasing the likelihood of successful treatments for a range of diseases. Ultimately, the application of such innovative approaches in pharmaceutical research signifies a significant leap forward in the quest for effective and targeted drug therapies.

RNA Therapeutics Targeting GPCRs

The field of RNA based therapeutics has gained significant traction in recent years, offering new opportunities for targeting GPCRs that may be difficult to modulate through traditional small molecule drugs. Techniques such as antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and messenger RNA (mRNA) therapies are being explored for their potential to modulate GPCR expression and activity [10].



Fig 2: Downstream Signalling

RNA therapeutics provide a unique advantage by allowing for the selective silencing of specific GPCRs at the mRNA level, bypassing the need to directly target the receptor itself. This approach has shown promise in treating diseases where receptor dysregulation is a key factor, such as in certain cancers, genetic disorders and rare diseases caused by specific GPCR mutations. For example, RNA based therapies targeting the mRNA of specific GPCRs could potentially correct dysfunctional signalling pathways without affecting the entire receptor family.

While challenges such as delivery mechanisms and stability issues remain, advancements in nanoparticle-based delivery systems and chemical modifications to RNA molecules are making RNA-based approaches more feasible. These strategies open up new avenues for treating diseases previously considered "undruggable" due to the complexity and specificity of GPCR targets.

Synthetic Biology and GPCR Engineering

Synthetic biology has emerged as a powerful tool for advancing GPCR-based drug discovery. By engineering GPCRs into synthetic gene circuits, researchers can control receptor activity with high precision, creating therapeutic outputs in response to specific signals [11]. This approach allows for the construction of biosensors, which can be used to monitor GPCR activity in real-time and screen for new drug candidates.

Additionally, GPCR-based optogenetics tools have made it possible to control receptor activation with light, providing a novel means of modulating cellular signalling in both research and therapeutic settings. By incorporating light-sensitive GPCRs into synthetic circuits, scientists can study the temporal dynamics of receptor signalling and its role in disease processes. These innovations hold the potential to revolutionize cell-based therapies, enabling more precise and personalized treatments for a range of conditions, from neurological disorders to cancer.

Orphan GPCRs and Emerging Targets

Orphan G protein-coupled receptors (GPCRs) are a unique class of receptors that have garnered significant attention in the scientific community due to their distinctive characteristic of lacking identified endogenous ligands. This elusive nature has presented formidable challenges in the domain of drug discovery and development. For many years, these orphan receptors were shrouded in mystery, largely because their biological functions and potential therapeutic applications had not been comprehensively elucidated.

However, recent strides in high-throughput screening technologies, coupled with advanced computational modelling techniques, are beginning to illuminate these obscure pharmacological targets.

Researchers are increasingly capable of identifying candidate ligands that may interact with orphan GPCRs. These interactions are crucial for unravelling the physiological roles these receptors play and their associated signalling pathways, which could be fundamental to our understanding of various biological processes.

A prime example of an orphan GPCR making waves in research is GPR88. This receptor has been identified as a significant contributor to various neuropsychiatric disorders, including schizophrenia and depression. Furthermore, GPR88 has been implicated in neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The emerging evidence highlighting GPR88's involvement in these health conditions underscores its potential as a critical target for therapeutic intervention.

By concentrating efforts on understanding orphan GPCRs like GPR88, scientists are optimistic about unlocking new pathways for drug development. Research into these receptors could lead to the creation of innovative treatment strategies that address unmet medical needs, particularly in the areas of mental health and neurodegenerative disorders. The ongoing exploration of orphan GPCRs is expected to pave the way for novel therapeutics that could significantly enhance treatment options for patients suffering from these complex diseases. [12]



Fig:3: Neurodegenerative Disorders

Researchers are increasingly using advanced computer tools to predict how ligands interact with receptors, especially focusing on orphan G protein-coupled receptors (GPCRs) that don't have known ligands. By using modelling techniques and simulations, they can identify possible binding partners and learn how these difficult-to-study receptors work.

Alongside these computer methods, researchers are implementing high-throughput screening techniques. These methods allow them to test many compounds against orphan GPCRs quickly. This combination of predictive modelling and efficient screening speeds up the process of discovering new drugs.

As a result of these efforts, orphan receptors are being recognized as valuable targets for drug discovery. This is important for tackling diseases that currently have no effective treatments, as success in this area could lead to new therapies for conditions that have been tough to treat. Overall, research focused on orphan GPCRs shows their potential to change the landscape of treatments and offer new hope for patients in need.

Targeting Cryptic and Allosteric Sites

Cryptic binding pockets are hidden sites on GPCRs that are not readily apparent in static structural models but can become accessible during conformational changes. These pockets represent untapped potential for drug discovery, offering the possibility of highly selective and novel therapeutic targets [13]. Advances in molecular dynamics simulations and AI-driven methods have made it possible to identify and exploit these cryptic binding sites, which could lead to the development of drugs with fewer side effects and greater specificity.



Fig 4: Targeting Sites of GPCR

Targeting these hidden sites is a promising strategy for overcoming challenges associated with traditional drug discovery, such as the development of resistance or off-target effects. Cryptic sites are often located in regions that are involved in receptor activation, providing an opportunity for drugs that modulate receptor function in a unique and specific manner.

Clinical Applications and Future Directions

GPCR-targeted therapies are already widely used in clinical settings, from cardiovascular agents like beta-blockers to CNS-targeted treatments for disorders such as Parkinson's disease and schizophrenia. The growing body of research on GPCRs is expanding the possibilities for future therapies, particularly with the advent of precision medicine and the use of advanced technologies such as gene editing, RNA therapeutics and synthetic biology.

As new GPCR targets are identified, particularly orphan receptors and cryptic sites, the scope for novel therapies continues to broaden. The integration of multi-disciplinary approaches, including structural biology, AI and genomics, will be essential for uncovering new therapeutic strategies. The future of GPCR drug discovery lies in its ability to provide targeted, personalized treatments for a wide array of diseases [7].

CONCLUSION

G-protein coupled receptors (GPCRs) are central to modern drug discovery due to their role in various physiological responses and unique structural features that allow for pharmacological modulation. With over 800 different receptors in the human genome, GPCRs contribute to nearly all major biological systems, making them key targets for therapies in conditions such as cardiovascular and metabolic disorders, neurodegenerative diseases, and cancers.

The evolution of drug discovery tools, such as high-resolution structural biology, cryo-electron microscopy and AI-driven ligand prediction, has greatly improved the design of selective and potent GPCR-targeted therapeutics. Additionally, RNA therapeutics and synthetic biology offer new ways to modulate GPCR function with precision, expanding therapeutic approaches and enabling the targeting of previously 'undruggable' receptors.

The increasing focus on orphan GPCRs, allosteric modulators and cryptic binding sites presents a promising opportunity in drug development, potentially providing treatments for diseases without effective therapies. Interdisciplinary collaboration in structural biology, bioinformatics, pharmacology and medicinal chemistry will be crucial to understanding the complexities of GPCR signalling and pharmacology.

In conclusion, the therapeutic potential of GPCRs is vast and continues to grow with scientific advancements. A multi-pronged and interdisciplinary approach, integrating traditional pharmacology with cutting-edge technological innovations, will be instrumental in fully realising the promise of GPCRs in personalised and precision medicine. The future of GPCR-targeted drug discovery is poised to deliver not only more effective drugs but also transformative therapies for some of the most challenging diseases in modern medicine.

REFERENCES

1. Hauser AS et al. (2017). Trends in GPCR drug discovery: new agents, targets and indications. *Nature Reviews Drug Discovery*, 16(12), 829–842.
2. Venkatakrishnan, A. J., Deupi, X., & Kobilka, B. K. (2013). Molecular signatures of G-protein-coupled receptors. *Nature*, 495(7442), 383-388. https://pubmed.ncbi.nlm.nih.gov/23407534/
3. William I Weis. GPCR ligand binding and activation: Structural insights into receptor functionality. *Annual Review of Biochemistry, 87, 897–919.*https://pubmed.ncbi.nlm.nih.gov/18957321/
4. Daniel M. Rosenbaum, Søren G. F. Rasmussen & Brian K. Kobilka. The structure and function of G-protein-coupled receptors. https://www.nature.com/articles/nature08144
5. Christopoulos, A. (2014). Allosteric modulation of GPCRs: A potential avenue for drug discovery. *Annual Review of Pharmacology and Toxicology*, 54, 389-409. https://doi.org/10.1146/annurev-pharmtox-011613-135914
6. Eric A. Wold, Jianping Chen, Kathryn A. Cunningham, Jia Zhou. Allosteric Modulation of Class A GPCRs. https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b00875
7. Raschka, S. (2020). Artificial intelligence and machine learning in GPCR-ligand prediction. *arXiv*, 2001.06545. https://arxiv.org/abs/2001.06545
8. Kim, S., et al. (2023). GPCR-BERT: A protein language model for predicting ligand interactions. *arXiv*, 2310.19915. https://arxiv.org/abs/2310.19915
9. Jacob, L., et al. (2008). Virtual screening of GPCRs: an in silico chemogenomics approach. *arXiv*, 0801.4301. https://arxiv.org/abs/0801.4301
10. Wanjun Yuan, Xiangyang Shi, Leo Tsz On Lee. RNA-based therapeutics targeting GPCRs for rare diseases. *Molecular Therapy - Nucleic Acids*, 28, 101-115. Molecular Therapy
11. Yasutomi Higashikuni, William CW Chen, Timothy K. Advancing therapeutic applications of synthetic gene circuits. https://www.sciencedirect.com/science/article/abs/pii/S0958166917301106
12. Jinuk Kim and Chulwon Choi (2024). Orphan GPCRs in neuropsychiatric and neurodegenerative disorders. *ACS Chemical Neuroscience*, 13(8), 1123-1135. https://www.mdpi.com/1467-3045/46/10/691
13. Nussinov, R., et al. (2019). Allosteric modulation of GPCRs: insights into the dynamic nature of receptor function *Trends in Pharmacological Sciences*, 40(6), 351–364. https://www.cell.com/cell/fulltext/S0092-8674(16)31064-9
14. Katritch, V., et al. (2010). Structure-based discovery of novel chemotypes for adenosine A2A receptor antagonists. *Trends in Pharmacological Sciences*, 34(12), 667–677. https://pubmed.ncbi.nlm.nih.gov/20095623/
15. Alexander, S. P., et al. (2019). "The concise guide to pharmacology 2019/20: G protein-coupled receptors." *British Journal of Pharmacology*, 176(S1), S1-S53. https://pubmed.ncbi.nlm.nih.gov/31710717/